Lice infestation

Summary

Lice infestation (MONDO:0003472) is a disease and 18 clinical trials. Top therapeutic interventions include permethrin, spinosad, and abametapir. A subtype of parasitic ectoparasitic infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lice infestation
Mondo ID	MONDO:0003472
MeSH	D010373
DOID	DOID:5502
ICD-10-CM	B85.2
NCIT	C128401
UMLS	C0030756
MedGen	18339
Is cancer (heuristic)	no

Also known as: infections, Pediculus humanus · louse infestation (& [pediculosis and Phthirus] or [lice]) · mixed pediculosis infestation · pediculosis · pediculosis and Phthirus infestation · pediculosis, unspecified · Pediculus humanus infection

Disease family

This is a subtype of parasitic ectoparasitic infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › parasitic skin disorder › parasitic ectoparasitic infectious disease › lice infestation

Related subtypes (5): mite infestation, tick infestation, myiasis, tungiasis, external hirudiniasis

Subtypes (3): Pthirus pubis infestation, Pediculus humanus capitis infestation, Pediculus humanus corporis infestation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Abametapir	Approved (phase 4)
Benzyl Alcohol	Approved (phase 4)
Ivermectin	Approved (phase 4)
Spinosad	Approved (phase 4)
Coco Diethanolamide	Phase 3 (in late-stage trials)
Malathion	Phase 3 (in late-stage trials)
Permethrin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Lindane.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	6
PHASE2/PHASE3	3
PHASE1	3
PHASE4	2
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01660321	PHASE4	COMPLETED	Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
NCT05565820	PHASE4	COMPLETED	A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation
NCT00244439	PHASE3	COMPLETED	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
NCT00381082	PHASE2/PHASE3	COMPLETED	A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.
NCT00545753	PHASE3	COMPLETED	Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
NCT00752973	PHASE2/PHASE3	COMPLETED	Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
NCT00819520	PHASE3	COMPLETED	Ivermectin in the Treatment of Head Lice
NCT00927472	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
NCT00963508	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
NCT01966965	PHASE3	UNKNOWN	Efficacy and Safety Study for PIOLIN® Shampoo
NCT02499549	PHASE2/PHASE3	TERMINATED	Two Treatment Regimens of Cocamide DEA Lotion for Head Lice
NCT00291057	PHASE2	TERMINATED	Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
NCT01336647	PHASE2	COMPLETED	An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation
NCT00927407	PHASE1	COMPLETED	Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice
NCT01518699	PHASE1	COMPLETED	Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
NCT05643820	PHASE1	COMPLETED	Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis
NCT00207753	Not specified	COMPLETED	Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
NCT00731718	Not specified	COMPLETED	Control of Head Lice Infestations in Children and Adults

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PERMETHRIN	4	5
SPINOSAD	4	2
ABAMETAPIR	4	1
IVERMECTIN	4	1
MALATHION	4	1
COCO DIETHANOLAMIDE	3	1
CHEMBL2040681	0	2
CHEMBL263291	0	2
CHEMBL4082099	0	1
CHEMBL4788951	0	1